Fezolinetant Reduces Vasomotor Symptoms in Menopause
The safety and efficacy of fezolinetant in the treatment of menopause-related vasomotor symptoms were assessed.
The safety and efficacy of fezolinetant in the treatment of menopause-related vasomotor symptoms were assessed.
Global population numbers are predicted to peak in several decades and then shrink by 50% in some countries; researchers want to know why.
Investigators evaluated the effect of gender-affirming hormone therapy on markers associated with systemic, endothelial, or adipose tissue-related inflammation, as well as platelet activation and coagulation.
Study finds increased risk for severe disease and mortality among men hospitalized with COVID-19 and low testosterone and high estradiol-to-testosterone ratio.